Unlike traditional assay interference, which can usually be overridden by simple sample dilution, LER represents a true "masking" of the endotoxin. The endotoxin particles are physically altered or hidden by components within the drug formulation itself, rendering them invisible to traditional Limulus Amebocyte Lysate (LAL) assays. The Molecular Mechanism of LER
The PDA first published Technical Report 82 in 2015, with the aim of providing a detailed framework for evaluating sterile compounding facilities. The report was developed by a team of experts with extensive experience in sterile compounding, facility design, and regulatory compliance. TR 82 provides guidance on the key elements of sterile compounding facilities, including design, construction, and operation. pda technical report 82
[ Active Endotoxin Aggregate ] │ ▼ + Chelating Agent (e.g., Citrate/EDTA) [ Stripped Divalent Cations (Mg2+/Ca2+) ] │ ▼ + Polysorbate Surfactant (PS20/PS80) [ Micellar Re-arrangement / Monomer Coating ] │ ▼ [ Masked Endotoxin (Invisible to LAL) ] Unlike traditional assay interference, which can usually be
For those needing to perform these specialized studies, laboratories like Microcoat and bioMérieux offer dedicated based on TR 82 guidelines. Technical Report No. 82 "Low Endotoxin Recovery" The report was developed by a team of
According to TR 82, LER typically arises from a driven by a combination of a surfactant and a chelating agent: